Sector News

Alexion scraps R&D programs, lays off staff after setbacks

March 14, 2017
Life sciences

Alexion Pharmaceuticals is set to lay off 7% of its staff and scrap some R&D programs to restructure its business following a tricky period.

The move sees the recently appointed interim CEO-CFO team stamp their mark on a biotech that is coming off the back of R&D setbacks and an internal probe into fraud allegations.

With Alexion having a 3,000-plus workforce at the last count, the restructuring, news of which was broken by Bloomberg and confirmed by Reuters, is set to cost approximately 200 people their jobs. Alexion is yet to say whether some units will bear the brunt of the company-wide restructuring, or disclose exactly where the ax will fall on its R&D programs. The company may provide more details when it discusses its first quarter results.

Alexion has been more forthcoming about the pipeline prospects it will focus its attention on after its has finished the restructuring. Talking to analysts at Barclays, Alexion picked out development of longer-acting anti-C5 antibody ALXN1210 in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome (aHUS)—the indications in which Soliris is approved—and cancer asset samalizumab as two of its priorities. Alexion also remains focused on developing Soliris for use in neuromyelitis optica and myasthenia gravis.

Absent from the list is SBC-103, the drug Alexion acquired in its $8.4 billion takeover of Synageva. Alexion took an $85 million impairment charge against the candidate and revealed it isn’t planning any further studies around the turn of the year.

News of the setback to SBC-103 emerged in a period in which then-CEO David Hallal and CFO Vikas Sinha left and the company began an internal probe into fraud allegations. These issues, coupled to worries Soliris will one day cease to be a cash cow, have driven down Alexion’s stock by 10% over the past year.

“Given the recent management change and conservative guidance, we are not surprised that the company is planning on optimizing its workforce and reevaluating some R&D programs. In speaking with the company, this restructuring was planned and incorporated in 2017 guidance provided on the 4Q16 earnings call,” Barclays analyst Geoff Meacham, Ph.D., wrote in a note to investors.

By Nick Paul Taylor

Source: Fierce Biotech

comments closed

Related News

April 20, 2024

CureVac and MD Anderson Cancer Center partner to develop new cancer vaccines

Life sciences

CureVac and the University of Texas’s MD Anderson Cancer Center have announced a co-development and licensing agreement to develop novel messenger ribonucleic acid (mRNA)-based cancer vaccines. The strategic collaboration will focus on the development of differentiated cancer vaccine candidates in selected haematological and solid tumour indications with high unmet medical needs.

April 20, 2024

FUJIFILM plans $1.2 billion investment in major US manufacturing facility

Life sciences

FUJIFILM Corporation is planning to invest $1.2 billion to expand the planned FUJIFILM Diosynth Biotechnologies manufacturing facility in Holly Springs, North Carolina, US. This news follows the organisation’s announcement of a $2 billion investment in the facility in March 2021. This additional financial boost totals the investment to over $3.2 billion, FUJIFILM confirmed.

April 20, 2024

Sanofi cuts staff in Belgium as early-stage research dwindles

Life sciences

Sanofi’s global restructuring and downsizing is now fully underway, with layoffs stretching to the company’s Belgian offices. Belgian newspaper De Tijd reports that 67 employees have been laid off at a site in Ghent and 32 jobs are on the chopping block at Sanofi’s Belgium HQ in Diegem.

How can we help you?

We're easy to reach